The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Optimizing belantamab mafodotin dosing and ocular toxicity management in myeloma
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses practical considerations for the use of belantamab mafodotin in multiple myeloma. Dr Ocio reviews dosing strategies aimed at maintaining efficacy while reducing corneal toxicity, and highlights the importance of early ophthalmologic monitoring and proactive toxicity management in routine clinical practice. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
